Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile (C. difficile) infection will be presented as part of an invited talk at Digestive Disease Week® (DDW) 2021. The congress will take place virtually from May 21-23, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005129/en/
“These data are the pinnacle of a decade of ground-breaking research and development, driven by the goal of helping those who are experiencing the debilitating effects of recurrent C. difficile infection,” said Lee Jones, Founder, President and Chief Executive Officer of Rebiotix, a Ferring Company. “We’re striving to deliver innovative therapeutics to help people live better lives, and are proud to be pioneering a new category of scientifically-validated, microbiome-based therapeutics that are standardized for quality and safety. We’re looking forward to sharing this milestone data with the entire community at DDW.”
The clinical development program for RBX2660 is the largest and most robust ever conducted in the field of microbiome-based therapeutics, including six clinical trials enrolling more than 1,000 patients to date.
C. difficile infection is a serious and potentially deadly disease that impacts people across the globe. Declared a public health threat by the U.S. Centers for Disease Control and Prevention (CDC) requiring urgent and immediate action, C. difficile infection causes an estimated half a million illnesses and tens of thousands of deaths in the U.S. alone each year.1,2,3 C. difficile infection recurs in up to 35% of cases after initial diagnosis4,5 and people who have had a recurrence are at significantly higher risk of further infections.6,7,8,9 Recurrent C. difficile infection (rCDI) is associated with disruptions to the gut microbiome, or “dysbiosis”. The current standard of care treatment for rCDI is antibiotics, which does not address the underlying dysbiosis or restore the gut microbiome.10
To further amplify the impact of this devastating disease, Ferring will also present an analysis of mortality rates and healthcare costs among Medicare patients with primary C. difficile infection and rCDI in cohorts of patients with and without sepsis. Sepsis, the body’s extreme response to an infection and a life-threatening medical emergency11, can be a complication of C. difficile infection.
The details of the three presentations are as follows:
Session Number: 2155
Session Title: Beyond FMT: A Pragmatic Approach to Microbiome Therapies: RBX2660 Study
Presenting Author: Christine Lee, MD, FRCPC, Clinical Professor, Department of Pathology and Laboratory Medicine, UBC Faculty of Medicine; Medical Microbiologist and Researcher, Island Health
EMBARGOED UNTIL PRESENTATION TIME: FRIDAY, MAY 21 AT 1:24 PM ET
Session Number: 6320
Poster Number: Sa611
Title: Interim Analysis of a Phase 3 Open-Label Study Indicates Safety and Efficacy of RBX2660, an Investigational Live Biotherapeutic, in a “Real-World” Population of Patients With Recurrent Clostridioides difficile Infection
Presenting Author: Colleen Kraft, MD, Associate Professor, Division of Infectious Diseases, Emory University School of Medicine
EMBARGOED UNTIL PRESENTATION TIME: SATURDAY, MAY 22 AT 12:15 PM ET
Session Number: 5345
Poster Number: Fr559
Title: A Real-World Comparison of Mortality, Healthcare Resource Utilization, and Cost Among Medicare Beneficiaries with Clostridioides difficile Infection With and Without Sepsis
Presenting Author: Alpesh Amin, MD, MBA, Thomas & Mary Cesario Chairman, Department of Medicine, Executive Director, Hospitalist Program, University of California – Irvine
EMBARGOED UNTIL PRESENTATION TIME: FRIDAY, MAY 21 AT 12:15 PM ET
DDW has made abstracts available on their website.
RBX2660 is a potential first-in-class microbiota-based live biotherapeutic being studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection. RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). The pivotal Phase 3 program builds on nearly a decade of research with robust clinical and microbiome data collected over six controlled clinical trials with more than 1,000 participants.
About the gut microbiome and C. difficile infection
The gut microbiome is a highly-diverse microbial community that plays an essential role in human health. There is a growing body of evidence that shows when there is a disruption of the composition and/or diversity of the gut microbiome, there may be an associated risk for serious illnesses, such as C. difficile infection.
C. difficile is a bacterium that causes debilitating symptoms such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea and colitis (an inflammation of the colon).1 Estimated to cause up to half a million illnesses and thousands of deaths annually in the U.S. alone every year, C. difficile infection is considered an urgent threat to public health by the CDC and can lead to severe complications, including hospitalization, surgery, sepsis and death.1,2 C. difficile infection is often the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system.12,13 The use of antibiotics has been shown to disrupt the ecology of the gut microbiome, and are a predominant risk factor for C. difficile recurrence – occurring in up to 35% of patients after initial C. difficile infection diagnosis.4,5,10 After the first recurrence, it has been estimated that up to 60% of patients may develop a subsequent recurrence.14
Restoring the gut microbiome is increasingly accepted as a promising treatment option for recurrent C. difficile infection.15
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. Connect with us on our dedicated microbiome therapeutics development channels on Twitter and LinkedIn.
Rebiotix Inc, a Ferring Company, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix has a diverse pipeline of investigational drug products built on its pioneering microbiota-based MRT™ drug platform. The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com, or connect with us on Twitter, Facebook, LinkedIn and YouTube.
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is a fully virtual meeting from May 21-23, 2021. The meeting showcases more than 2,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
- Centers for Disease Control and Prevention. What Is C. Diff? 17 Dec. 2018. Available at: https://www.cdc.gov/cdiff/what-is.html.
- Centers for Disease Control and Prevention. Biggest Threats and Data. 14 Nov. 2019. Available at: https://www.cdc.gov/drugresistance/biggest-threats.html.
- Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile infections. Clin Microbiol Infect. 2012;18(suppl 6):2-4.
- Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-834.
- Cornely OA, et al. Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin. Clinical Infectious Diseases. 2012;55(S2):S154–61.
- Riddle DJ, Dubberke ER. Clostridium difficile infection in the intensive care unit. Infect Dis Clin North Am. 2009;23(3):727-743.
- Nelson WW, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims. J Manag Care Spec Pharm. Published online March 11, 2021.
- Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012; 18 (Suppl. 6): 21–27.
- Smits WK, et al. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. doi: 10.1038/nrdp.2016.20.
- Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39.
- Centers for Disease Control and Prevention. Sepsis. 27 Jan. 2021. Available at: https://www.cdc.gov/sepsis/what-is-sepsis.html.
- Centers for Disease Control and Prevention. 24 June 2020. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf.
- Feuerstadt P, et al. J Med Econ. 2020;23(6):603-609.
- Leong C, Zelenitsky S. Treatment strategies for recurrent Clostridium difficile infection. Can J Hosp Pharm. 2013;66(6):361-368.
- van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For more information, please contact
Director, Brand Communications
Communications & Digital Innovation
Associate Director, Marketing and Communications
Rebiotix Inc, a Ferring Company
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Luminary Launches New Subscription Channel on Apple Podcasts15.6.2021 22:27:00 EEST | Press release
Luminary, a subscription podcast network, today launched a new channel on Apple Podcasts, making all Luminary Original podcasts available globally to Apple Podcasts listeners in more than 170 countries. “We’re thrilled to collaborate with Apple, the house that built podcasting, to bring our original content to millions of listeners across the world,” said Simon Sutton, Luminary CEO. “When we founded Luminary, we believed that supporting premium subscription podcast content was important to listeners and creators alike. Distributing our content on Apple Podcasts is a critical step in fulfilling our vision,” said Matt Sacks, Luminary Co-founder and Executive Chairman. The Luminary channel includes more than 30 Luminary Original podcasts including Under the Skin with Russell Brand, Snap Judgment Presents: Spooked, The C-Word with Lena Dunham, and Leon Neyfakh’s Fiasco. The Luminary channel also includes access to The Midnight Miracle, a new show from creators Talib Kweli, yasiin bey, and
Pony.ai Becomes First Company to Test Driverless Vehicles on Public Roads in Both the U.S. and China15.6.2021 22:00:00 EEST | Press release
Silicon Valley-based Pony.ai, a leading autonomous driving company, today announced that it has begun regular and daily fully driverless testing on public roads in Fremont and Milpitas, CA. Along with the recent launch of fully driverless testing in Guangzhou, China, the company has become the first to get fully driverless automated vehicles on public roads in three cities across the world's two most dynamic mobility markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005458/en/ The successful kick-off is authorized by the previously announced driverless permit received from the California Department of Motor Vehicles for a fleet of six driverless vehicles, facilitating the total operational coverage over 100 square kilometers. Countless stealth technology iterations and numerous driverless readiness evaluations executed by a top-notch team have reinforced this significant milestone. As U.S. cities reopen in phases
Proteintech Group Celebrates 20-Year Anniversary15.6.2021 18:09:00 EEST | Press release
Proteintech Group, a leading manufacturer of antibodies and related products, is celebrating the 20th anniversary of its founding. To celebrate the achievements and challenges of the past years, Proteintech will host special events throughout the year with its customers, collaborators, and employees while still looking forward to future opportunities. “Over the years we have witnessed countless discoveries and we couldn’t be prouder of everything our customers have achieved. We want to thank all of our customer for their tireless efforts and sacrifices to advance scientific discovery,” Dr. Jason Li, CEO Proteintech Group was founded in early 2001 by a small group of scientists including its current CEO, Dr. Jason Li. The founders set out with a vision to produce an antibody for every single protein coded in the human genome. Comprehensive coverage of all human gene products is a massive undertaking, but critical because it is difficult for researchers to predict which targets may be re
Norsk Titanium Expands into the Industrial Application Market in Collaboration with Hittech Group15.6.2021 18:00:00 EEST | Press release
Norsk Titanium AS (Norsk Titanium; Euronext: NTI), a global leader in additive manufacturing of aerospace-grade titanium components, announced an expansion of its customer base into the industrial application market sector in collaboration with the Hittech Group, based in Den Haag, Netherlands. The production of the first industrial component in this development supports a Hittech end customer in the growing semiconductor equipment market. Norsk expects significant near-term investment by manufacturers in the semiconductor market as they seek to modernize their supply chains. This effort represents Norsk’s first step to support these modernization efforts with a faster, more cost efficient and environmentally friendly approach. Using Norsk’s revolutionary Rapid Plasma Deposition™ (RPD™) process, Norsk engineers have designed a titanium alloy preform that will reduce Hittech’s raw material needs by over 45 percent as compared to legacy wrought product used to fabricate the end component
i2c Becomes First Company to be a Visa Fintech Fast Track Member in Four Regions15.6.2021 17:15:00 EEST | Press release
i2c, a leading provider of digital payment and banking technology, today announced the extension of its membership in Visa’s Fintech Fast Track program to the Asia-Pacific region (AP), making it the first company to become an enablement partner in all four regions of the acclaimed program. As an enablement partner, i2c helps lay the foundation for fintechs to build and expand their products locally, regionally or globally over its single stack, modular platform. Designed to accelerate the process of integrating with Visa, the Fintech Fast Track program brings together services and expertise to support fintech companies in their efforts to launch payments solutions. Partners leverage the payment network’s reach, capabilities, and security to realize faster onboarding times, and allow fintechs to scale more quickly. “We are excited to be able to simplify the process of launching a card program in 10 more countries, as an extension of our commitment to being a truly global partner for our
Viking Malt: Foundation Stone Laid: Construction of the New Production Plant in Lahti, Finland, is Progressing as Planned15.6.2021 17:04:00 EEST | Press release
Viking Malt has laid the foundation stone for its new production plant in Lahti. The plan is that the new malting house will start its operations in 2023. It is about 90 million euro project in size and the production capacity will be ca. 85 000 tons per year. Owner Pär-Gustaf Relander and CEO Kasper Madsen hosted the ceremony at the construction site on Pippo-Kujala industrial area. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005825/en/ The time capsule and the representants from Construction Consultant Afry, Viking Malt and the Mayor of Lahti, Pekka Timonen. Photo by Viking Malt. The company is already over 130 years old and the key to success has always been to focus on high quality and to be open to innovation and new technology. The new plant is a continuation of this tradition. Building a new plant gives a unique opportunity to utilize the newest technology to both increase efficiency and to become more enviro
New Data Shows $30 Billion Streaming Advertising Disconnect Among Publishers, Brands and Consumers15.6.2021 17:00:00 EEST | Press release
Conviva, the intelligence cloud for streaming media, released its inaugural State of Streaming Advertising report today, revealing big gaps in how publishers, buyers and consumers perceive streaming ads, and what this means for the future of the multibillion dollar streaming ad industry. For example, while 69% of sellers believe ad quality on streaming is as good as on linear television, just over half of buyers feel similarly (55%) and only about a third of consumers agree (35%). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005329/en/ Conviva's State of Streaming Advertising 2021 (Graphic: Business Wire) “With streaming, there is an opportunity to provide high-quality creative to consumers, but we need to evaluate how and when we reach them,” said Scott McDonald, President & CEO, Advertising Research Foundation (ARF). “It’s time to move on from 1:1 targeting, with growing concerns over privacy and the challenge of s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom